Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Europace ; 25(9)2023 08 02.
Artículo en Inglés | MEDLINE | ID: mdl-37470443

RESUMEN

AIMS: Electro-anatomical mapping may be critical to identify atrial fibrillation (AF) subjects who require substrate modification beyond pulmonary vein isolation (PVI). The objective was to determine correlations between pre-ablation mapping characteristics and 12-month outcomes after a single PVI-only catheter ablation of AF. METHODS AND RESULTS: This study enrolled paroxysmal AF (PAF), early persistent AF (PsAF; 7 days-3 months), and non-early PsAF (>3-12 months) subjects undergoing de novo PVI-only radiofrequency catheter ablation. Sinus rhythm (SR) and AF voltage maps were created with the Advisor HD Grid™ Mapping Catheter, Sensor Enabled™ for each subject, and the presence of low-voltage area (LVA) (low-voltage cutoffs: 0.1-1.5 mV) was investigated. Follow-up visits were at 3, 6, and 12 months, with a 24-h Holter monitor at 12 months. A Cox proportional hazards model identified associations between mapping data and 12-month recurrence after a single PVI procedure. The study enrolled 300 subjects (113 PAF, 86 early PsAF, and 101 non-early PsAF) at 18 centres. At 12 months, 75.5% of subjects were free from AF/atrial flutter (AFL)/atrial tachycardia (AT) recurrence. Univariate analysis found that arrhythmia recurrence did not correlate with AF diagnosis, but LVA was significantly correlated. Low-voltage area (<0.5 mV) >28% of the left atrium in SR [hazard ratio (HR): 4.82, 95% confidence interval (CI): 2.08-11.18; P = 0.0003] and >72% in AF (HR: 5.66, 95% CI: 2.34-13.69; P = 0.0001) was associated with a higher risk of AF/AFL/AT recurrence at 12 months. CONCLUSION: Larger extension of LVA was associated with an increased risk of arrhythmia recurrence. These subjects may benefit from substrate modification beyond PVI.


Asunto(s)
Fibrilación Atrial , Aleteo Atrial , Ablación por Catéter , Venas Pulmonares , Humanos , Fibrilación Atrial/diagnóstico , Fibrilación Atrial/cirugía , Venas Pulmonares/cirugía , Frecuencia Cardíaca , Resultado del Tratamiento , Técnicas Electrofisiológicas Cardíacas , Recurrencia , Factores de Tiempo , Atrios Cardíacos , Aleteo Atrial/diagnóstico , Aleteo Atrial/cirugía , Aleteo Atrial/etiología , Ablación por Catéter/efectos adversos , Ablación por Catéter/métodos
2.
G Ital Cardiol (Rome) ; 21(10): 768-778, 2020 Oct.
Artículo en Italiano | MEDLINE | ID: mdl-32968314

RESUMEN

Electrical storm (ES) is defined as three or more episodes of sustained ventricular tachycardia (VT) or fibrillation (VF) within 24 h, or an incessant VT/VF lasting more than 12 h. It usually occurs in implantable cardioverter-defibrillator (ICD) recipients, and three or more device interventions are typically used for the diagnosis. ES incidence is particularly high in case of ICD implanted in secondary prevention (10-30%), with recurrences occurring in up to 80% of patients. A comprehensive evaluation of triggers, predictive factors of high-risk patients and an appropriate management of the acute/subacute and chronic phases are pivotal to reduce mortality and recurrences. Medical therapy with antiarrhythmic and anesthetic drugs, with appropriate device reprogramming and neuroaxial modulation if needed, are used to cool down the ES, which should ultimately be treated with ablation therapy or, less often, with an alternative treatment, such as denervation or stereotactic radiosurgery. An optimization of the clinical pathway in a network modeling is crucial to achieve the best treatment, eventually addressing patients to centers with VT ablation programs, and identifying the most challenging procedures and the most critical patients that should be treated only in high-volume tertiary centers. In this paper, we present a proposal of healthcare network modeling for ES treatment in a regional setting.


Asunto(s)
Modelos Teóricos , Taquicardia Ventricular/terapia , Fibrilación Ventricular/terapia , Anestésicos/administración & dosificación , Antiarrítmicos/administración & dosificación , Vías Clínicas , Desfibriladores Implantables/efectos adversos , Atención a la Salud , Sinapsis Eléctricas , Humanos , Incidencia , Factores de Riesgo , Taquicardia Ventricular/fisiopatología , Factores de Tiempo , Fibrilación Ventricular/fisiopatología
3.
Int J Cardiovasc Imaging ; 36(9): 1599-1607, 2020 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-32447632

RESUMEN

To evaluate predictors of zero-X ray procedures for supraventricular arrhythmias (SVT) using minimally fluoroscopic approach (MFA). Patients referred for RF catheter ablation of SVT were admitted for a MFA with an electro-anatomical navigation system or a conventional fluoroscopic approach (ConvA). Exclusion criterion was the need to perform a transseptal puncture. 206 patients (98 men, age 53 ± 19 years) underwent an EP study, 93 (45%) with an MFA and 113 (55%) with a ConvA. Fifty-five had no inducible arrhythmias (EPS). Fifty-four had AV nodal reentrant tachycardia (AVNRT), 49 patients had typical atrial flutter (AFL), 37 had AV reciprocating tachycardia (AVRT/WPW), 11 had focal atrial tachycardia (AT), and underwent a RF ablation. X-ray was not used at all in 51/93 (58%) procedures (zero X ray). MFA was associated with a significant reduction in total fluoroscopy time (5.5 ± 10 vs 13 ± 18 min, P = 0.01) and operator radiation dose (0.8 ± 2.5 vs 3 ± 8.2 mSV, P < 0.05). The greatest absolute dose reduction was observed in AVNRT (0.1 ± 0.3 vs 5.1 ± 10 mSV, P = 0.01, 98% relative dose reduction) and in AFL (1.3 ± 3.6 vs 11 ± 16 mSV, P = 0.003, 88% relative dose reduction) groups. Both AVNRT or AFL resulted the only statistically significant predictors of zero x ray at multivariate analysis (OR 4.5, 95% CI 1.5-13 and OR 5, 95% CI 1.7-15, P < 0.001, respectively). Success and complication rate was comparable between groups (P = NS). Using MFA for SVT ablation, radiological exposure is significantly reduced. Type of arrhythmia is the strongest predictor of zero X ray procedure.


Asunto(s)
Aleteo Atrial/cirugía , Ablación por Catéter , Exposición Profesional/prevención & control , Dosis de Radiación , Exposición a la Radiación/prevención & control , Taquicardia por Reentrada en el Nodo Atrioventricular/cirugía , Taquicardia Supraventricular/cirugía , Potenciales de Acción , Adulto , Anciano , Aleteo Atrial/diagnóstico por imagen , Aleteo Atrial/fisiopatología , Ablación por Catéter/efectos adversos , Técnicas Electrofisiológicas Cardíacas , Femenino , Fluoroscopía , Frecuencia Cardíaca , Humanos , Masculino , Persona de Mediana Edad , Exposición Profesional/efectos adversos , Seguridad del Paciente , Exposición a la Radiación/efectos adversos , Estudios Retrospectivos , Medición de Riesgo , Factores de Riesgo , Taquicardia por Reentrada en el Nodo Atrioventricular/diagnóstico por imagen , Taquicardia por Reentrada en el Nodo Atrioventricular/fisiopatología , Taquicardia Supraventricular/diagnóstico por imagen , Taquicardia Supraventricular/fisiopatología , Factores de Tiempo , Resultado del Tratamiento
5.
Mycopathologia ; 175(1-2): 129-34, 2013 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-23073824

RESUMEN

We report on the treatment with micafungin of a pacemaker-associated endocarditis due to Candida albicans. Antifungal therapy was able to reduce vegetation size from 5 to 1 cm making possible the transvenous removal of the device without a high risk of pulmonary embolism. Noteworthy, a high micafungin concentration was documented into the lead vegetation (10 µg/g of vegetation tissue) and this may have contributed to the striking size reduction of vegetation.


Asunto(s)
Antifúngicos/uso terapéutico , Candida albicans/aislamiento & purificación , Equinocandinas/uso terapéutico , Endocarditis/diagnóstico , Endocarditis/tratamiento farmacológico , Lipopéptidos/uso terapéutico , Marcapaso Artificial/efectos adversos , Prótesis e Implantes/efectos adversos , Anciano , Candida albicans/efectos de los fármacos , Ecocardiografía , Endocarditis/microbiología , Endocarditis/patología , Femenino , Humanos , Micafungina , Pruebas de Sensibilidad Microbiana , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA